Second-generation antipsychotics for anxiety disorders
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Anxiety disorders are common and disabling conditions, with a lifetime prevalence of 17% in the general population. Due to high rates of treatment resistance, there is interest in new pharmacological treatment options such as second-generation antipsychotics. OBJECTIVES: To evaluate the efficacy and tolerability of second-generation antipsychotics as monotherapy or adjunctive treatment for people with anxiety disorders. SEARCH STRATEGY: The Cochrane Depression, Anxiety and Neurosis Group's controlled trial registers (CCDANCTR-Studies and CCDANCTR-References) were searched up to 21 July 2010. The author team ran complementary searches on ClinicalTrials.gov. SELECTION CRITERIA: We included all randomised trials (RCTs) comparing second-generation antipsychotic drugs with placebo, benzodiazepines, pregabalin or antidepressants. Participants were people with generalised anxiety disorder, panic disorder and specific phobias including social phobia. DATA COLLECTION AND ANALYSIS: Two authors extracted data independently. For dichotomous data we calculated odds ratios (OR) and their 95% confidence intervals (CI). For continuous data we calculated mean differences (MD) based on a random-effects model. MAIN RESULTS: The review currently includes eleven RCTs with 4144 participants on three second-generation antipsychotics (olanzapine, quetiapine, risperidone). Nine studies investigated the effects of second-generation antipsychotics in generalised anxiety disorder, only two studies investigated the effects in social phobia. There were no studies on panic disorder or any other primary anxiety disorder.Seven studies investigated the effects of quetiapine. Participants with generalised anxiety disorder responded significantly better to quetiapine than to placebo (4 RCTs, N = 2265, OR = 2.21, 95% CI 1.10 to 4.45). However, they were more likely to drop out due to adverse events, to gain weight, to suffer from sedation or to suffer from extrapyramidal side effects. When quetiapine was compared with antidepressants, there was no significant difference in efficacy-related outcomes, but more participants in the quetiapine groups dropped out due to adverse events, gained weight and feeling sedated. Only two very small studies with a total of 36 participants examined olanzapine and found no difference in response to treatment. Two trials compared adjunctive treatment with risperidone with placebo and found no difference in response to treatment. AUTHORS' CONCLUSIONS: We identified eligible trials on quetiapine, risperidone and olanzapine. The available data on olanzapine and risperidone are too limited to draw any conclusions. Monotherapy with quetiapine seems to be efficacious in reducing symptoms of generalised anxiety disorder and this effect may be similar to that of antidepressants. However, quetiapine's efficacy must be weighed against its lower tolerability.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The empirical status of cognitive-behavioral therapy: A review of meta-analyses
Butler, A. C., Chapman, J. E., Forman, E. M., & Beck, A. T. (2006) · Clinical Psychology Review · doi:10.1016/j.cpr.2005.07.003 · Cited by 3,215
Moher, D. (2001) · JAMA · doi:10.1001/jama.285.15.1987 · Cited by 2,545
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
Meta-analyses involving cross-over trials: methodological issues
Elbourne, D. R., Altman, D. G., Higgins, J. P., Curtin, F., Worthington, H. V., & Vail, A. (2002) · International Journal of Epidemiology · doi:10.1093/ije/31.1.140 · Cited by 2,305
Liebowitz, M. R. (2015) · Modern Trends in Pharmacopsychiatry · doi:10.1159/000414022 · Cited by 2,266
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
Self-citationImputing missing standard deviations in meta-analyses can provide accurate results
Furukawa, T. A., Barbui, C., Cipriani, A., Brambilla, P., & Watanabe, N. (2006) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.06.006 · Cited by 1,568
Statistics Notes: Detecting skewness from summary information: Table 1
Altman, D. G., & Bland, J. M. (1996) · BMJ · doi:10.1136/bmj.313.7066.1200 · Cited by 1,278
Prevalence and incidence studies of anxiety disorders: A systematic review of the literature
Somers, J. M., Goldner, E. M., Waraich, P., & Hsu, L. (2006) · The Canadian Journal of Psychiatry · doi:10.1177/070674370605100206 · Cited by 1,114
Multicenter Collaborative Panic Disorder Severity Scale
Shear, M. K., Brown, T. A., Barlow, D. H., Money, R., Sholomskas, D. E., Woods, S. W., Gorman, J. M., & Papp, L. A. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.11.1571 · Cited by 1,001
The unit of analysis error in studies about physicians' patient care behavior
Divine, G. W., Brown, J. T., & Frazier, L. M. (1992) · Journal of General Internal Medicine · doi:10.1007/bf02599201 · Cited by 749
Cognitive Behavioral Group Therapy vs Phenelzine Therapy for Social Phobia: 12-Week Outcome
Heimberg, R. G., Liebowitz, M. R., Hope, D. A., Schneier, F. R., Holt, C. S., Welkowitz, L. A., Juster, H. R., Campeas, R., Bruch, M. A., Cloitre, M., et al. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.12.1133 · Cited by 585
Psychological and Pharmacological Treatments of Social Phobia: A Meta-Analysis
Fedoroff, I. C., & Taylor, S. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200106000-00011 · Cited by 396
Treatment-resistant anxiety disorders
Bystritsky, A. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001852 · Cited by 289
Grant, B. F., Hasin, D. S., Stinson, F. S., Dawson, D. A., Goldstein, R. B., Smith, S., Huang, B., & Saha, T. D. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0305 · Cited by 258
Bandelow, B., Chouinard, G., Bobes, J., Ahokas, A., Eggens, I., Liu, S., & Eriksson, H. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990423 · Cited by 142
Munk-Jørgensen, P., Allgulander, C., Dahl, A. A., Foldager, L., Holm, M., Rasmussen, I., Virta, A., Huuhtanen, M.-T., & Wittchen, H.-U. (2006) · Psychiatric Services · doi:10.1176/ps.2006.57.12.1738 · Cited by 96
Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety
Sheehan, D. V., McElroy, S. L., Harnett-Sheehan, K., Keck, P. E., Janavs, J., Rogers, J., Gonzalez, R., Shivakumar, G., & Suppes, T. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.10.005 · Cited by 69
Aripiprazole as Augmentation Treatment of Refractory Generalized Anxiety Disorder and Panic Disorder
Hoge, E. A., Worthington, J. J., Kaufman, R. E., Delong, H. R., Pollack, M. H., & Simon, N. M. (2008) · CNS Spectrums · doi:10.1017/s109285290001676x · Cited by 58
Research works printed but not linked: 43
- Barnett, 2002, Efficacy of olanzapine in social anxiety disorder: a pilot study, Journal of Psychopharmacology, 16, 365, 10.1177/026988110201600412 · DOI · Paper page
- Brawman-Mintzer, 2005, Adjunctive risperidone in generalized anxiety disorder: a double blind, placebo-controlled study, Journal of Clinical Psychiatry, 66, 1321, 10.4088/JCP.v66n1016 · DOI · Paper page
- Pandina, 2007, Adjunctive risperidone in the treatment of generalized anxiety disorder: a double-blind, placebo-controlled, randomized trial, Psychopharmacology Bulletin, 40, 41
- Pollack, 2006, Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study, Biological Psychiatry, 59, 211, 10.1016/j.biopsych.2005.07.005 · DOI
- Simon, 2008, Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings, Psychopharmacology, 197, 675, 10.1007/s00213-008-1087-x · DOI
- Vaishnavi, 2007, Quetiapine as a monotherapy for social anxiety disorder: a placebo controlled study, Progress in Neuropsychopharmacology & Biological Psychiatry, 31, 1464, 10.1016/j.pnpbp.2007.06.027 · DOI
- Adson, 2004, Preliminary experience with adjunctive risperidone in patients receiving selective serotonin reuptake inhibitors, Depression and Anxiety, 19, 121, 10.1002/da.10137 · DOI · Paper page
- Adson, 2005, Treatment of anxiety symptoms with adjunctive aripiprazole in depressed patients taking serotonin reuptake inhibitors, Journal of Affective Disorders, 86, 99, 10.1016/j.jad.2004.11.007 · DOI
- Menza, 2007, An open label trial of aripiprazole augmentation for treatment resistant generalized anxiety disorder, Journal of Clinical Psychopharmacology, 27, 207, 10.1097/01.jcp.0000248620.34541.bc · DOI · Paper page
- Prosser, 2009, A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: a randomised, single-blind study, BMC Psychiatry, 9, 25, 10.1186/1471-244X-9-25 · DOI · Paper page
- Sepede, 2006, Olanzapine augmentation in treatment resistant panic disorder: a 12 week fixed-dosed open-label-trial, Journal of Clinical Psychopharmacology, 26, 45, 10.1097/01.jcp.0000195108.01898.17 · DOI · Paper page
- Simon, 2006, An open label trial of risperidone augmentation for refractory anxiety disorders, Journal of Clinical Psychiatry, 67, 381, 10.4088/JCP.v67n0307 · DOI · Paper page
- Wilner, 2002, The anxiolytic effect of the novel antipsychotic ziprasidone compared with diazepam in subjects anxious before dental surgery, Journal of Clinical Psychopharmacology, 22, 206, 10.1097/00004714-200204000-00016 · DOI
- Worthington, 2005, Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients, International Clinical Psychopharmacology, 20, 9, 10.1097/00004850-200501000-00002 · DOI · Paper page
- Donahue, 2009, Effect of quetiapine vs. placebo on response to two virtual public speaking exposures in individuals with social phobia, Journal of Anxiety Disorders, 23, 362, 10.1016/j.janxdis.2008.12.004 · DOI
- Lohoff, 2010, Ziprasidone treatment of refractory gneralized anxiety disorder : a placebo-controlled, double-blind study, Journal of Clinical Psychopharnmacology, 30, 185, 10.1097/JCP.0b013e3181d21951 · DOI · Paper page
- American Psychiatric Association, 1980, Diagnostic and Statistical Manual of Mental Disorders, 3rd edition (DSM III)
- American Psychiatric Association, 1987, Diagnostic and Statistical Manual of Mental Disorders, 3rd edition - revised (DSM-III-R)
- American Psychiatric Association, 1994, Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV)
- Arnt, 1998, Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence, Neuropsychopharmacology, 18, 63, 10.1016/S0893-133X(97)00112-7 · DOI · Paper page
- Bland, 1997, Statistics notes. Trials randomised in clusters, BMJ, 315, 600, 10.1136/bmj.315.7108.600 · DOI · Paper page
- Correll, 2004, Lower risk for tardive dyskinesia associated with second generation antipsychotics: a systematic review of one-year studies, American Journal of Psychiatry, 161, 414, 10.1176/appi.ajp.161.3.414 · DOI · Paper page
- Davidson, 1997, The Brief Social Phobia Scale: a psychometric evaluation, Psychological Medicine, 27, 161, 10.1017/S0033291796004217 · DOI · Paper page
- Der-Simonian, 1986, Meta-analysis in clinical trials, Controlled Clinical Trials, 7, 177, 10.1016/0197-2456(86)90046-2 · DOI · Paper page
- Gao, 2006, Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: A review, Journal of Clinical Psychiatry, 67, 1327, 10.4088/JCP.v67n0902 · DOI · Paper page
- Gulliford, 1999, Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994, American Journal of Epidemiology, 149, 876, 10.1093/oxfordjournals.aje.a009904 · DOI · Paper page
- Guy, 1976, Clinical Global Impressions - ECDEU Asessment Manual Psychopharmacology (DHEW Publ No ADM 76-338)
- Hamilton, 1959, The assessment of anxiety states by rating, British Journal of Medical Psychology, 32, 50, 10.1111/j.2044-8341.1959.tb00467.x · DOI · Paper page
- Hamilton, 1960, A rating scale of depression, Journal of Neurology, 23, 56
- Heres, 2006, Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine, American Journal of Psychiatry, 163, 185, 10.1176/appi.ajp.163.2.185 · DOI · Paper page
- Higgins, 2003, Measuring inconsistency in meta-analyses, BMJ, 327, 557, 10.1136/bmj.327.7414.557 · DOI · Paper page
- Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008] The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org 2008 · DOI · Paper page
- Ipser, 2006, Pharmacotherapy augmentation strategies in treatment resistant augmentation disoders, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD005473.pub2 · DOI · Paper page
- Ipser, 2009, Pharmacotherapy for anxiety disorder in children and adolescents, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD005170.pub2 · DOI · Paper page
- Kessler, 1994, Lifetime and 12-month prevalence of DSM-III psychiatric disorders in the United States, Archives of General Psychiatry, 51, 975, 10.1001/archpsyc.1994.03950010008002 · DOI · Paper page
- Komossa, 2009, Second-generation antipsychotic drugs for obsessive compulsive disorder, Cochrane Database of Systematic Reviews
- Montgomery, 1979, A new depression scale designed to be sensitive to change, British Journal of Psychiatry, 134, 382, 10.1192/bjp.134.4.382 · DOI · Paper page
- Newcomer, 2005, Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review, CNS Drugs, 19, 1, 10.2165/00023210-200519001-00001 · DOI · Paper page
- Raj, 1987, Medical evaluation of panic attacks, Journal of Clinical Psychiatry, 48, 309
- Sajatovic, 2003, Treatment for mood and anxiety disorders: quetiapine and aripiprazole, Current Psychiatry Reports, 5, 320, 10.1007/s11920-003-0062-9 · DOI
- Stein, 2000, Pharmacotherapy for social anxiety disorder, Cochrane Database of Systematic Reviews
- Vital, 2007, Seroquel led antipsychotics sales in 2006, Clinical Psychiatric News, 35, 1
- World Health Organisation, 1992, International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10)
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“Atypical antipsychotics: Atypical antipsychotics are associated to varying degrees with weight gain, diabetes, and other metabolic side effects, including alterations in glucose and lipid levels [109-116].”
BackgroundInfluentialBaldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
“The potential value of antipsychotic drug monotherapy in acute treatment is unknown [I (M)] (Depping et al., 2010).”
BackgroundMaher, A. R., Maglione, M., Bagley, S., Suttorp, M., Hu, J.-H., Ewing, B., Wang, Z., Timmer, M., Sultzer, D., & Shekelle, P. G. (2011) · JAMA · doi:10.1001/jama.2011.1360 · Cited by 558
Szuhany, K. L., & Simon, N. M. (2022) · JAMA · doi:10.1001/jama.2022.22744 · Cited by 541
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.595584 · Cited by 440
Metadata
- Authors
- Depping, A. M., Komossa, K., Kissling, W., & Leucht, S.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2010-12-08
- Issue
- 12
- Pages
- CD008120-CD008120
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1738433183
- Cited by
- 86
- References
- 19
- FWCI
- 9.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.